Milton C. Ault III - 31 Jan 2024 Form 4 Insider Report for Alzamend Neuro, Inc. (ALZN)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALZN	Series A Convertible Preferred Stock	Purchase	$1,220,000	-1,220	-50%	$1000.00^*	1,220	31 Jan 2024	Common Stock	1,220,000	$1.00	By Ault Life Sciences Fund, LLC	F1, F2, F3
transaction	ALZN	Warrants	Purchase	$0	-1,220,000	-50%	$0.000000	1,220,000	31 Jan 2024	Common Stock	1,220,000	$1.20	By Ault Life Sciences Fund, LLC	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The shares of series A convertible preferred stock (the "Series A Convertible Preferred Stock") have no expiration date.
F2	Each share of Series A Convertible Preferred Stock has a stated value of $1,000 (the "Stated Value") and is convertible into a number of shares of common stock determined by dividing the Stated Value by the conversion price, which is currently $1.00.
F3	Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Ault Alliance, Inc. ("AAI"). Mr. Ault, the Executive Chairman of AAI, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.
F4	These warrants were issued for no additional consideration in connection with the purchase of the Series A Convertible Preferred Stock.